Human leukocyte antigen (HLA) and pharmacogenetics: Screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta

Human Immunology

Volumn 73, Issue 2, 2012, Pages 164-167

  Berka, Noureddine ^a,b   Gill, John M ^b,c   Liacini, Abdelhamid ^a,b   O'Bryan, Tyler ^c   Khan, Faisal M ^a,b  

^a CALGARY LABORATORY SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Southern Alberta HIV Clinic   (Canada)

Author keywords

Abacavir; B*57:01; HIV; HLA; Pharmacogenetics

Indexed keywords

ABACAVIR; HLA B ANTIGEN;

ABACAVIR HYPERSENSITIVITY SYNDROME; ADULT; ALLELE; ARTICLE; CANADA; CONTROLLED STUDY; DATA ANALYSIS; DRESS SYNDROME; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALBERTA; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; GENETIC TESTING; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES;

EID: 84856343062     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.12.002     Document Type: Article

References (25)

1. Rawlins M.D., Thompson J.W. Mechanisms of adverse drug reactions. Textbook of adverse drug reactions 1991, 18-45. Oxford University Press, Oxford. D.M. Davies (Ed.).
2. Davies S.J., Jackson P.R., Ramsay L.E., Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Arch Intern Med 2003, 163:592-600.
3. Park B.K., Pirmohamed M., Kitteringham N.R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992, 34:377-395.
4. Pichler W.J., Beeler A., Keller M., et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int 2006, 55:17-25.
5. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B-57:01, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
6. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
7. Saag M.S., Balu R., Phillips E., Brachman P., Martorell C., Burman W., et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008, 46:1111-1118.
8. Hetherington S., Hughes A.R., Mosteller M., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
9. Kostenko L., Kjer-Nielsen L., Nicholson I., Hudson F., Lucas A., Foley B., et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 2011, 78:11-20.
10. Hung S.I., Chung W.H., Liou L.B., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005, 102:4134-4139.
11. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
12. Man C.B.L., Kwan P., Baum L., Yu E., Lau K.M., Cheng A.S.H., et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
13. Locharernkul C., Loplumlert J., Limotai C., Korkij W., Desudchit T., Tongkobpetch S., et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008, 49:2087-2091.
14. Singer J.B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-714.
15. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832.
16. Khan F.M., Gill J., Schollaardt T., Christina C., Berka N. HLA and pharmacogenetics: dissecting the functional mechanism behind strong association of HLA-B*5701 with abacavir hypersensitivity. Hum Immunol 2009, 70:S1.
17. Higgs J., Gambhir N., Ramsden S.C., Poulton K., Newman W.G. Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genet Test Mol Biomark 2010, 14:121-125.
18. Martin A.M., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004, 101:4180-4185.
19. Phillips E., Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009, 13:1-9.
20. Rauch A., Nolan D., Thurnheer C., Fux C.A., Cavassini M., Chave J.P., et al. Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008, 13:1019-1028.
21. Barber L.D., Percival L., Arnett K.L., Gumperz J.E., Chen L., Parham P. Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J Immunol 1997, 158:1660-1669.
22. Duraiswamy J., Burrows J.M., Bharadwaj M., Burrows S.R., Cooper L., Pimtanothai N., et al. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J Virol 2003, 77:7401-7410.
23. Orkin C., Sadiq S.T., Rice L., Jackson F. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med 2010, 11:187-192. UK EPI team.
24. Hammond E., Almeida C.A., Mamotte D., Nolan D., Phillips E., Schollaardt T.A., et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther 2007, 12:1027-1032.
25. Peters B.J., Rodin A.S., de Boer A., Maitland-van der Zee A.H. Methodological and statistical issues in pharmacogenomics. J Pharm Pharmacol 2010, 62:161-166.